Form 4: Corcept Therapeutics Executive Gary Robb Reports Stock Transactions

Gary Robb, Chief Business Officer of Corcept Therapeutics, reports the disposition and acquisition of company stock via sales and gifts.

Summary

• Gary Charles Robb, Chief Business Officer of Corcept Therapeutics, filed a Form 4 detailing changes in beneficial ownership.
• On May 20, 2025, Robb sold 2,279 shares of common stock at $75.85 per share.
• On the same day, Robb gifted 1,380 shares of common stock.
• Robb also gifted 360 shares of common stock to a custodial account for a child.
• Following these transactions, Robb directly owns 16,586 shares and indirectly owns 11,571 shares through a custodial account.
• The directly owned shares include 1,818 unvested restricted stock awards granted on June 3, 2024, 503 shares granted on September 3, 2024, 290 shares granted on December 2, 2024, and 292 shares granted on March 3, 2025, which vest on the one-year anniversary of the grant date.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing reporting stock transactions. It doesn't inherently convey positive or negative sentiment, but rather provides factual information about an executive's trading activity.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the trading activities of company insiders. Investors often monitor these filings to gauge executive sentiment and potential future stock performance.

Stakeholder Impact

• Shareholders may be interested in the stock transactions of company executives as an indicator of company performance and future prospects.

Key Dates

Keywords

Form 4, Beneficial Ownership, Stock Sale, Stock Gift, Corcept Therapeutics, CORT, Gary Robb, Executive, Securities